AUROPHARMA Intraday Analysis...

AUROPHARMA Share Price

Open 962.00 Change Price %
High 972.00 1 Day 16.50 1.73
Low 955.05 1 Week 4.10 0.43
Close 968.45 1 Month 0.20 0.02
Volume 1215328 1 Year 751.75 346.91
52 Week High 1002.30
52 Week Low 217.00
AUROPHARMA Important Levels
Resistance 2 984.16
Resistance 1 977.69
Pivot 965.17
Support 1 959.21
Support 2 952.74
AUROPHARMA CURRENT MONTH FUTURE
Close 974.80
Contracts Traded 9508
Open Intrest 8078000
Change In O.I 279000
Lot Size 250
AUROPHARMA CURRENT MONTH OPTION
Most Active Call 1000
Most Active put 960
Highest O.I Buildup Call 1060
Highest O.I Buildup Put 940
Expiry Date 27-Nov-2014
AUROPHARMA ALL MONTHS OPTIONS
For All AUROPHARMA Options Click Here
NSE INDIA Most Active Stocks
NIFTY 8322.20 1.87%
UNITECH 20.50 6.22%
JPASSOCIAT 31.15 2.81%
LITL 6.65 -0.75%
GMRINFRA 21.65 2.61%
IDFC 156.30 5.43%
SUZLON 13.45 2.28%
GVKPIL 11.70 9.86%
VKSPL 0.25 -16.67%
ALOKTEXT 12.50 5.93%
More..
NSE INDIA Top Gainers Stocks
SHRIRAMEPC 39.60 20.00%
ARCHIDPLY 33.05 19.96%
PANCARBON 281.60 19.65%
ONMOBILE 39.05 19.05%
REISIXTEN 0.35 16.67%
CHROMATIC 5.65 16.49%
KTIL 370.75 14.02%
NCC 59.65 13.30%
NCC 59.65 13.30%
IFBIND 412.00 12.37%
More..
NSE INDIA Top Losers Stocks
VKSPL 0.25 -16.67%
NGCT 1.50 -16.67%
FCSSOFT 0.35 -12.50%
SEPOWER 5.50 -11.29%
AROGRANITE 75.00 -10.23%
BANARBEADS 46.95 -9.10%
GLFL 2.60 -8.77%
BILENERGY 1.60 -8.57%
BILPOWER 1.65 -8.33%
POCHIRAJU 32.30 -8.11%
More..

Aurobindo Pharma Limited (NSE: AUROPHARMA)

AUROPHARMA Technical Analysis 5
As on 31st Oct 2014 AUROPHARMA Share Price closed @ 968.45 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 613.98 & Strong Buy for SHORT-TERM with Stoploss of 869.35 we also expect STOCK to react on Following IMPORTANT LEVELS.
AUROPHARMA Target for November
1st Target up-side 1086.9
2nd Target up-side 1170.06
3rd Target up-side 1253.22
1st Target down-side 849.6
2nd Target down-side 766.44
3rd Target down-side 683.28
AUROPHARMA Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 68.32 Sideways
MFI (14) MFI is 54.52 Sideways
CCI (20) CCI is -13.16 Sideways
WILLIAM %R (14) William %R is -42.53 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 658.30
10 Day Avg Volume Traded 16.95 % More then 10 Day Average Volume
AUROPHARMA Other Details
Segment EQ
Market Capital 25150871552.00
Sector Pharmaceuticals
Industry
Offical website
AUROPHARMA Address
AUROPHARMA
N/A
 
AUROPHARMA Latest News
Aurobindo Pharma tanks 5% despite strong fourth quarter nos   Moneycontrol.com   - 02nd Jun 14
TABLE-India's Aurobindo Pharma Jan-March net profit rises   Reuters   - 31st May 14
Aurobindo Pharma Q4 net spurts to Rs 501 cr   Hindu Business Line   - 30th May 14
Morgan Stanley sells Aurobindo Pharma shares worth Rs 116cr   Moneycontrol.com   - 30th May 14
Buy Aurobindo Pharma Ltd with a target of Rs 670: Mitesh Thacker   Economic Times   - 28th May 14
Reddy Becomes Billionaire as India's Aurobindo Shares Triple   Bloomberg   - 27th May 14
Aurobindo Pharma to announce FY14 results on May 30, 2014   Equity Bulls   - 27th May 14
Aurobindo Pharma rallies nearly 3%, hits fresh 52-week high on MSCI inclusion   Economic Times   - 15th May 14
Aurobindo Pharma hits new high   Business Standard   - 13th May 14
Aurobindo Pharma Limited   Moneycontrol.com   - 12th May 14
Interactive Technical Analysis Chart Aurobindo Pharma Limited ( AUROPHARMA NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Aurobindo Pharma Limited
AUROPHARMA Business Profile
Aurobindo Pharm is in the Pharmaceuticals sector. Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others. Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India. The current market capitalisation stands at Rs 8,284.96 crore.The company has reported a consolidated sales of Rs 1913.86 crore and a Net Profit of Rs 233.86 crore for the quarter ended Sep 2013. The company management includes K Ragunathan - Non Executive Chairman, K Nithyananda Reddy - Vice Chairman & Whole Time Dir, N Govindarajan - Managing Director, M Sivakumaran - Whole Time Director, M Madan Mohan Reddy - Whole Time Director, P V Ramprasad Reddy - Non Executive Director, P Sarath Chandra Reddy - Non Executive Director, M Sitarama Murthy - Non Executive Director, D Rajagopala Reddy - Non Executive Director, C Channa Reddy - Non Executive Director. It is listed on the BSE with a BSE Code of 524804 and the NSE with an NSE Code of AUROPHARMA. Its Registered office is at Plot No. 2, Maitrivihar,,Ameerpet Hyderabad,Andhra Pradesh - 500038.